Company Overview - Biophytis is focused on developing therapeutics to slow degenerative processes associated with aging, including treatments for severe respiratory failure in COVID-19 patients[5]. - The company is based in Paris, France, and Cambridge, Massachusetts[5]. - The company’s ordinary shares are listed on Euronext Growth (Ticker: ALBPS) and ADSs on Nasdaq Capital Market (Ticker: BPTS)[5]. Drug Development - The leading drug candidate, Sarconeos (BIO101), is in a Phase 2 clinical trial for sarcopenia in the U.S. and Europe, with positive results from a Phase 2-3 study (COVA) for severe COVID-19 patients released in Q1 2023[5]. - A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD)[5]. Corporate Governance - The company held an Extraordinary General Meeting on March 30, 2023, which was adjourned due to insufficient quorum; a second call is scheduled for April 17, 2023[3][4]. - The quorum required for the Extraordinary General Meeting on the first call was 25%[3]. Financial Information - The company has not provided specific financial performance metrics or guidance in the current release[7]. - Forward-looking statements in the press release are subject to various risks and uncertainties, and actual outcomes may differ materially[7]. Investor Relations - Contact information for investor relations is provided, including CFO Philippe Rousseau[8].
Biophytis(BPTS) - 2023 Q1 - Quarterly Report